Market Overview

Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th

Related CYCC
Cyclacel Announces First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease,
Cyclacel Pharmaceuticals Shares Surge After Q4 Results

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders announced today that updated Phase 3 clinical trial results for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML) treated with sapacitabine and decitabine administered in alternating cycles will be presented at a poster presentation during the 54^th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, on Sunday, December 9, 2012.

The poster's abstract details are as follows:

Abstract: 2630 Pooled Analysis of Elderly Patients with Newly Diagnosed AML Title: Treated with Sapacitabine and Decitabine Administered in Alternating Cycles Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM Eastern Time   Hall B1-B2, Level 1, Building B (Georgia World Congress Center) Session: Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster II     Poster board: The abstract is available online at:

Posted-In: News


Related Articles (CYCC + CYCCP)

Get Benzinga's Newsletters